Impact of Early Lung Physiology, Viral Infections and the Microbiota on the Development and Progression of Lung Disease in Children With Cystic Fibrosis
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- Nasal swabs
Study Overview
Brief Summary
This study collects data on microbiological factors and lung function parameters (e.g. spirometry, body plethysmography, lung-MRI) to assess their interaction on the lung growth and lung development of infants and children with Cystic Fibrosis (CF).
Detailed Description
Background:
Cystic fibrosis (CF) is the most common lethal inherited disease in North European populations, affecting approximately 1:2500 live births. It is a multisystem disorder with respiratory morbidity and mortality being the leading cause of death. Lung disease in CF is characterized by neutrophil-dominated inflammation and chronic bacterial infection of the airways, which results in deterioration of lung function and premature death [1]. Despite improved survival in successive birth cohorts, the current median survival age of patients with CF is about 40 years [2]. Understanding the initiating events of CF lung disease (e.g viral infections and microbiome) and their influence on disease progression throughout early childhood is essential to improve survival through targeted early interventions.
Objectives:
The overarching aim of this study is to identify early life predictors of disease progression in children with CF. Therefore, this study implies three objectives, as follows: i) to investigate the effect of respiratory viral infections on microbiota dynamics in the first year of life in infants with CF, and to examine their influence on lung function at 1 year of age; ii) to examine whether deficits in lung function in the first year of life in infants with CF persist to pre- and school age and adolescence and are associated with impaired functional and structural abnormalities at 3, 6, 9, 12, 15 and 18 years of age; and iii) to determine the principal drivers of impaired lung function at 1 year and impaired lung function and structural outcomes at 3, 6, 9, 12, 15 and 18 years of age in individuals with CF.
Methods:
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 0 Years to 18 Years (Child, Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Infants with a confirmed diagnosis of CF by NBS
- •Age <=18 years
- •Written informed consent by patient and/or parent
Exclusion Criteria
- •Need for respiratory support for more than three days
- •Severe malformations or known diseases other than CF
- •Maternal drug abuse
- •Known severe maternal disease
- •Severe Problems of communication
- •Pacemaker, continuous glucose monitor
Outcomes
Primary Outcomes
Nasal swabs
Time Frame: At the age of 4-8 weeks, 1, 3, 6, 9, 12, 15 and 18 years
Longitudinal assessment of viral and bacterial colonization of the nasal swab
Multiple Breath Washout
Time Frame: Every third year from the age of 4-8 weeks/1 year till 18 years.
Longitudinal assessment of lung volume and ventilation inhomogeneity
Spirometry
Time Frame: Every third year from the age of 4-8 weeks/1 year till 18 years.
Longitudinal assessment of long volumes.
Body plethysmography
Time Frame: Every third year from the age of 4-8 weeks/1 year till 18 years.
Longitudinal assessment of ventilation inhomogeneity.
Magnetic Resonance Imaging (MRI)
Time Frame: At the age of 4-8 weeks, 1, 3, 6, 9, 12, 15 and 18 years
Longitudinal assessment of regional lung perfusion and ventilation
Weekly swabs
Time Frame: Weekly from the visit at the age of 4-8 weeks till the age of 1 year
Respiratory virus and bacterial diagnostic
Swabs during respiratory infection
Time Frame: From the visit at the age of 4-8 weeks till the age of 1 year
Respiratory viruses and Bacteria, changes of the microbial flora
Routine swabs in CF
Time Frame: At the age of 4-8 weeks, 1 year and at each 3-monthly clinic visit during the age of 3, 6, 9, 12, 15 and 18 years
Longitudinal assessment of bacterial changes, changes of the resistome (genes conferring antibiotic resistance) and the changes of the microbial flora
Secondary Outcomes
- Respiratory Rate (RR)(From the visit at the age of 4-8 weeks till the age of 1 year)
- Sweat test(At the age of 3, 6, 9, 12, 15 and 18 years)
